Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Pan Afr Med J ; 41: 329, 2022.
Artigo em Francês | MEDLINE | ID: mdl-35865833

RESUMO

Adnexal carcinomas are rare, accounting for less than 1% of skin carcinomas. Sclerosus carcinoma of the sweat glands was first described by Goldstein et al. in 1982. We here report the case of a 33-year-old female patient with a retracted perianal skin lesion. Histological examination of perilesional skin biopsy, immunohistochemistry, and negative results of laboratory tests, radiological and endoscopic investigations allowed for the diagnosis of eccrine sclerosus carcinoma. This is a rare tumor, usually characterized by facial localization and slow but aggressive progression. It poses problems in differential diagnosis with benign and malignant tumors; hence the challenge encountered by pathologist of suspecting this carcinoma in patients with any sclerotic and infiltrating skin lesion characterized by slow progression, in a context of preservation of the general state and in the absence of neoplastic history as well as of feeling free to ask for new deep biopsies when in doubt.


Assuntos
Neoplasias da Mama , Carcinoma de Apêndice Cutâneo , Carcinoma , Neoplasias Cutâneas , Neoplasias das Glândulas Sudoríparas , Adulto , Neoplasias da Mama/patologia , Carcinoma/patologia , Carcinoma de Apêndice Cutâneo/patologia , Diagnóstico Diferencial , Feminino , Humanos , Imuno-Histoquímica , Neoplasias Cutâneas/diagnóstico , Neoplasias Cutâneas/patologia , Neoplasias das Glândulas Sudoríparas/patologia
2.
Pan Afr Med J ; 32: 97, 2019.
Artigo em Francês | MEDLINE | ID: mdl-31223387

RESUMO

Darier and Ferrand dermatofibrosarcoma (DFS) is a rare skin tumor characterized by its local aggressiveness and a high risk of recurrences. Prognosis depends essentially on the quality of treatment. Complete response in Darier and Ferrand dermatofibrosarcoma with healthy margins, initially judged inoperable after 1 year of neoadjuvant imatinib-based treatment, has been rarely described in literature. We here report the case of a young female patient treated in the Department of Medical Oncology in FES for locally advanced DFS with complete response, in order to assess the role of imatinib and of targeted therapies in the treatment of DFS.


Assuntos
Antineoplásicos/administração & dosagem , Dermatofibrossarcoma/terapia , Mesilato de Imatinib/administração & dosagem , Neoplasias Cutâneas/terapia , Dermatofibrossarcoma/patologia , Feminino , Humanos , Terapia de Alvo Molecular , Terapia Neoadjuvante/métodos , Prognóstico , Neoplasias Cutâneas/patologia , Resultado do Tratamento , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA